Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

NCT03235167 is registered in ClinicalTrials.gov with Dalian University as lead sponsor.

NCT NCT03235167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03235167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy
Lead sponsor
Dalian University
Phase
Phase 1
Overall status
Unknown status
Start date
October 31, 2017
Completion date
October 31, 2022
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma